{"id":"lispro-mixture-therapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":{"chemblId":"CHEMBL1201538","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lispro Mixture combines two formulations of insulin lispro: the rapid-acting component addresses postprandial (after-meal) glucose spikes, while the protamine-complexed intermediate-acting component provides basal insulin coverage between meals and overnight. This dual-action approach approximates the body's natural biphasic insulin response to maintain glycemic control throughout the day.","oneSentence":"Lispro Mixture is a combination of rapid-acting insulin lispro and intermediate-acting insulin lispro protamine suspension that mimics physiologic insulin secretion by providing both mealtime and basal insulin coverage.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:52:33.816Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT02194595","phase":"PHASE3","title":"Preserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL)","status":"COMPLETED","sponsor":"Mount Sinai Hospital, Canada","startDate":"2014-09","conditions":"Type 2 Diabetes","enrollment":105},{"nctId":"NCT02432976","phase":"PHASE2, PHASE3","title":"Impact of Perioperative Exenatide Infusion on Quality of Life in Cardiac Surgery Patients","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2015-05","conditions":"Quality of Life","enrollment":64},{"nctId":"NCT02690883","phase":"PHASE4","title":"Effect of Exenatide on 24h-UAER in Patients With Diabetic Nephropathy","status":"COMPLETED","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2016-04-08","conditions":"Diabetic Nephropathies","enrollment":92},{"nctId":"NCT01269047","phase":"PHASE4","title":"Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia","status":"COMPLETED","sponsor":"Albert Einstein College of Medicine","startDate":"2009-08","conditions":"Type 1 Diabetes","enrollment":37},{"nctId":"NCT01969149","phase":"PHASE2, PHASE3","title":"Exenatide for Stress Hyperglycemia","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2015-01","conditions":"Stress Hyperglycemia","enrollment":110},{"nctId":"NCT02811484","phase":"PHASE4","title":"Efficacy of Exenatide-LAR and Dapagliflozin in Overweight/Obese, Insulin Treated Patients With Type 2 Diabetes","status":"WITHDRAWN","sponsor":"Weill Medical College of Cornell University","startDate":"2016-06","conditions":"Diabetes Mellitus, Type 2","enrollment":""},{"nctId":"NCT00960661","phase":"PHASE3","title":"A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-09","conditions":"Type 2 Diabetes Mellitus","enrollment":1036},{"nctId":"NCT01776788","phase":"PHASE4","title":"Effect of Short-Term Intensive Insulin Sequential Exenatide Therapy in Newly Diagnosed Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2012-08","conditions":"Diabetes Mellitus, Type 2","enrollment":156},{"nctId":"NCT01871493","phase":"PHASE1","title":"A Study of LY2605541 and Insulin Lispro Mixture in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-06","conditions":"Healthy Volunteers","enrollment":40},{"nctId":"NCT00971997","phase":"PHASE4","title":"A Study of Insulin Lispro Mix in Type 2 Diabetic Asian Patients","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2009-09","conditions":"Diabetes Mellitus, Type 2","enrollment":135},{"nctId":"NCT00664534","phase":"PHASE4","title":"Pre-Mix Insulin Lispro Treatment for Type 2 Diabetes Patients Who Consume a Light Breakfast","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2008-04","conditions":"Diabetes Mellitus, Type 2","enrollment":344},{"nctId":"NCT00279201","phase":"PHASE4","title":"The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2005-12","conditions":"Diabetes Mellitus, Type 2","enrollment":2091},{"nctId":"NCT00036504","phase":"PHASE4","title":"Efficacy and Safety of Twice-Daily Insulin Lispro Low Mixture Compared to a Once-Daily Long Acting Insulin Comparator in Patients Who Have Been Using One or More Oral Antihyperglycemic Agents Without Insulin","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2001-08","conditions":"Type 2 Diabetes Mellitus","enrollment":100},{"nctId":"NCT00191178","phase":"PHASE4","title":"Effects of Insulin in Perceived Mood Symptoms in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2003-08","conditions":"Type 2 Diabetes","enrollment":60},{"nctId":"NCT00551538","phase":"PHASE4","title":"24 Hour Plasma Glucose Profiles Comparing Lispro Mix 75/25 vs. Glargine","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2003-05","conditions":"Type 2 Diabetes","enrollment":15},{"nctId":"NCT00548808","phase":"PHASE4","title":"A Study for Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2007-11","conditions":"Type 2 Diabetes Mellitus","enrollment":426},{"nctId":"NCT00393705","phase":"PHASE4","title":"Lispro Mid Mixture (MM) Intensive Mixture Therapy With Progressive Dose-Titration of Lispro Low Mixture (LM) or Biphasic Insulin Aspart 30/70 (S019)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2006-10","conditions":"Diabetes Mellitus, Type 2","enrollment":302},{"nctId":"NCT00377858","phase":"PHASE4","title":"Comparison of Two Approaches to Insulin Therapy in Patients With Type 2 Diabetes (IOOX)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2006-08","conditions":"Diabetes Mellitus, Type 2","enrollment":484},{"nctId":"NCT00110370","phase":"PHASE4","title":"Comparing Pre-Mixed Insulin With Insulin Glargine Combined With Rapid-Acting Insulin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2004-04","conditions":"Diabetes Mellitus, Type 2","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Lispro Mixture Therapy","genericName":"Lispro Mixture Therapy","companyName":"Eli Lilly and Company","companyId":"eli-lilly-and-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lispro Mixture is a combination of rapid-acting insulin lispro and intermediate-acting insulin lispro protamine suspension that mimics the body's natural insulin secretion pattern to control blood glucose levels. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus requiring insulin therapy.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}